Alprazolam-ritonavir interaction: Implications for product labeling

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 4, 2000, Pages 335-341

  Greenblatt, David J ^a   Von Moltke, Lisa L ^b   Harmatz, Jerold S ^b   Durol, Anna Liza B ^b   Daily, Johanna P ^b   Graf, Jennifer A ^b   Mertzanis, Polyxane ^b   Hoffman, Jonathan L ^b   Shader, Richard I ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; PLACEBO; RITONAVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG LABELING; DRUG METABOLISM; FEMALE; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034056369     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.105757     Document Type: Article

References (29)

1. 1. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338:1281-92.
2. 2. Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999;36:289-304.
3. 3. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35:275-91.
4. 4. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998;38:106-11.
5. 5. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430.
6. 6. Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam: therapeutic implications. Clin Pharmacokinet 1993;24:453-71.
7. 7. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Shader RI. Alprazolam is another substrate for human cytochrome P450-3A isoforms [letter]. J Clin Psychopharmacol 1998;18:256.
8. 8. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31.
9. 9. Gorski JC, Jones DR, Hamman MA, Wrighton SA, Hall SD. Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica 1999;29:931-44.
10. 10. Frye R, Bertz R, Granneman GR, Qian J, Lamm J, Dennis S, Valdes J. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam (Abstract A-59). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada; 1997;37:12.
11. 11. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol 1999;19:293-6.
12. 12. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 1993;47:268-76.
13. 13. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-9.
14. 14. Greenblatt DJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, et al. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther 1998;64:237-47.
15. 15. Scavone JM, Greenblatt DJ, Harmatz JS, Engelhardt N, Shader RI. Pharmacokinetics and pharmacodynamics of diphenhydramine 25 mg in young and elderly volunteers. J Clin Pharmacol 1998;38:603-9.
16. 16. Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med 1991;324:1691-8.
17. 17. Greenblatt DJ, Javaid JI, Locniskar A, Harmatz JS, Shader RI. Gas Chromatographic analysis of alprazolam in plasma: replicability, stability, and specificity. J Chromatogr 1990;534:202-7.
18. 18. Granda BW, Giancarlo GM, von Moltke LL, Greenblatt DJ. Analysis of ritonavir in plasma/serum and tissues by high-performance liquid chromatography. J Pharmacol Toxicol Methods 1999;40:235-9.
19. 19. Schmider J, Brockmöller J, Arold G, Bauer S, Roots I. Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics 1999;9:725-34.
20. 20. Yaun R, Flockhart DA, Balian JD. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J Clin Pharmacol 1999;39:1109-25.
21. 21. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. Inhibition of triazolam hydroxylation by ketoconazole, itraconazole, hydroxyitraconazole and fluconazole in vitro. Pharm Pharmacol Commun 1998;4:443-5.
22. 22. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism in humans: clinical relevance. Clin Pharmacokinet 2000;38:111-80.
23. 23. Greenblatt DJ, Harmatz JS, Shader RI. Plasma alprazolam concentrations: relation to efficacy and side effects in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:715-22.
24. 14C-alprazolam, a new anxiolytic-antidepressant, in man [abstract]. Pharmacologist 1980;22:279.
25. 25. Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on the pharmacokinetics of alprazolam. Psychopharmacol Bull 1998;34:211-9.
26. 26. Gass RJA, Gal J, Fogle PW, Detmar-Hanna D, Gerber JG. Neither dapsone hydroxylation nor cortisol 6 beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors. Eur J Clin Pharmacol 1998;54:741-7.
27. 27. Quellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998;46:111-6.
28. 28. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
29. 29. Kastrissios H, Suarez JR, Katzenstein D, Girard P, Sheiner LB, Blaschke TF. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS 1998;12:2295-303.